Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects
Status:
Completed
Trial end date:
2017-03-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate bioequivalence between the test drug product,
fulvestrant Injection, 50 mg/mL, and the Reference Listed Drug, Faslodex® Injection, 50
mg/mL.